Oncotarget

Research Papers:

X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response

Zhixin Zhao _, Jianming Zhu, Haitian Quan, Guimin Wang, Bo Li, Weiliang Zhu, Chengying Xie and Liguang Lou

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:29648-29663. https://doi.org/10.18632/oncotarget.8818

Metrics: PDF 1100 views  |   HTML 1173 views  |   ?  


Abstract

Zhixin Zhao1,*, Jianming Zhu1,*, Haitian Quan1, Guimin Wang1, Bo Li1, Weiliang Zhu1, Chengying Xie1, Liguang Lou1

1Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China

*These authors have contributed equally to this work

Correspondence to:

Chengying Xie, e-mail: xiechengying818@simm.ac.cn

Liguang Lou, e-mail: lglou@mail.shcnc.ac.cn

Keywords: X66, HSP90, HSF-1, heat shock response, celastrol

Received: November 12, 2015    Accepted: March 28, 2016    Published: April 18, 2016

ABSTRACT

Heat shock protein 90 (HSP90) is essential for cancer cells to assist the function of various oncoproteins, and it has been recognized as a promising target in cancer therapy. Although the HSP90 inhibitors in clinical trials have shown encouraging clinical efficacy, these agents induce heat shock response (HSR), which undermines their therapeutic effects. In this report, we detailed the pharmacologic properties of 4-(2-((1H-indol-3-yl)methylene)hydrazinyl)-N-(4-bromophenyl)-6-(3,5- dimethyl-1H -pyrazol-1-yl)-1,3,5-triazin-2-amine (X66), a novel and potent HSP90 inhibitor. X66 binds to the N-terminal domain in a different manner from the classic HSP90 inhibitors. Cellular study showed that X66 depleted HSP90 client proteins, resulted in cell cycle arrest and apoptosis, and inhibition of proliferation in cancer cell lines. X66 did not activate heat shock factor-1 (HSF-1) or stimulate transcription of HSPs. Moreover, the combination of X66 with HSP90 and proteasome inhibitors yielded synergistic cytotoxicity which was involved in X66-mediated abrogation of HSR through inhibition of HSF-1 activity. The intraperitoneal administration of X66 alone depleted client protein and inhibited tumor growth, and led to enhanced activity when combined with celastrol as compared to either agent alone in BT-474 xenograft model. Collectively, the HSP90 inhibitory action and the potent antitumor activity, with the anti-HSR action, promise X66 a novel HSP90-targeted agent, which merits further research and development.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 8818